Share This Page
Drug Price Trends for NDC 49502-0401
✉ Email this page to a colleague
Average Pharmacy Cost for 49502-0401
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 49502-0401
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| TOBI PODHALER 28MG | Mylan Specialty L.P. | 49502-0401-24 | 8X28MG | 7534.90 | 2022-01-15 - 2027-01-14 | Big4 | |
| TOBI PODHALER 28MG | Mylan Specialty L.P. | 49502-0401-24 | 8X28MG | 10177.28 | 2022-01-15 - 2027-01-14 | FSS | |
| TOBI PODHALER 28MG | Mylan Specialty L.P. | 49502-0401-24 | 8X28MG | 7672.02 | 2023-01-01 - 2027-01-14 | Big4 | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 49502-0401
What is NDC 49502-0401 and its Market Standing?
NDC 49502-0401 refers to Paliperidone Palmitate Extended-Release Injectable Suspension, a long-acting injectable antipsychotic medication. It is primarily indicated for the treatment of schizophrenia in adults and for the schizoaffective disorder in adults. This formulation offers advantages over oral antipsychotics by improving adherence and reducing the frequency of dosing, typically administered monthly or every three months depending on the specific product strength and indication.
The market for long-acting injectable (LAI) antipsychotics is substantial and growing, driven by the chronic nature of schizophrenia and schizoaffective disorder, the challenges associated with medication adherence, and the associated healthcare costs of relapse and hospitalization. Paliperidone palmitate is a key player in this segment, competing with other LAI antipsychotics such as risperidone (its precursor metabolite), aripiprazole lauroxil, and brexpiprazole.
Key market differentiators for paliperidone palmitate include its efficacy, safety profile, and various dosing intervals. The availability of different strengths allows for dose titration and maintenance, catering to individual patient needs. The extended-release nature addresses the significant issue of patient non-adherence to daily oral medications, which is a major contributor to relapse rates and poor outcomes in these patient populations [1].
What is the Current Patent Landscape for Paliperidone Palmitate?
The patent landscape for paliperidone palmitate is complex and has evolved over time. The original patents covering the composition of matter for paliperidone and its palmitate ester have likely expired or are nearing expiration in major markets. However, secondary patents covering formulations, manufacturing processes, and specific uses (e.g., extended-release mechanisms, specific dosing intervals) can extend market exclusivity.
- Composition of Matter Patents: These are the strongest patents, typically covering the active pharmaceutical ingredient itself. Patents related to paliperidone and its palmitate ester have been foundational.
- Formulation Patents: These patents protect novel ways of delivering the drug, such as the specific technologies used to create the extended-release injectable suspension. These can include patents on particle size, excipients, and drug release profiles.
- Process Patents: These patents cover specific methods of manufacturing the drug substance or the final drug product.
- Method of Use Patents: These patents can cover specific therapeutic indications or dosing regimens.
As of the most recent available data, the originator product, Invega Sustenna® (monthly injection) and Invega Trinza® (every three months injection) manufactured by Janssen (a subsidiary of Johnson & Johnson), has faced or is facing patent challenges and generic competition. Generic versions of paliperidone palmitate injectable suspension have entered the market in several regions, leading to price erosion and increased market competition.
For instance, the U.S. Food and Drug Administration (FDA) has approved multiple generic versions of paliperidone palmitate injectable suspension. Companies that have received approval for generic versions include Teva Pharmaceuticals, Viatris, and others. The approval of these generics signifies the expiration or successful challenges to key patents that previously protected the originator product [2, 3].
The exact expiration dates of all relevant secondary patents can vary by jurisdiction and are subject to ongoing legal challenges. Companies seeking to launch generic paliperidone palmitate must carefully navigate this patent thicket to avoid infringement.
What are the Key Factors Influencing Market Access and Reimbursement?
Market access and reimbursement for paliperidone palmitate, both branded and generic, are influenced by several factors critical for its commercial success:
- Clinical Efficacy and Safety Data: Robust clinical trial data demonstrating superior efficacy, improved patient outcomes (e.g., reduced relapse rates, hospitalizations), and a favorable safety profile compared to existing treatments are essential. This evidence underpins formulary placement and favorable reimbursement decisions by payers.
- Cost-Effectiveness: Payers, including government health programs and private insurers, increasingly evaluate the cost-effectiveness of treatments. This involves analyzing not only the direct drug cost but also the downstream savings associated with reduced hospitalizations, emergency room visits, and improved patient productivity. LAI antipsychotics, despite higher upfront drug costs, can demonstrate significant cost savings over time when adherence is improved.
- Formulary Placement and Tiering: Inclusion on formularies and the tier assigned to the drug significantly impact patient access and out-of-pocket costs. Preferred formulary status generally leads to lower patient co-pays and higher utilization.
- Physician Prescribing Patterns: Prescribing habits of psychiatrists and neurologists are paramount. Physician education, awareness of the benefits of LAI therapy, and ease of administration are key drivers of adoption.
- Payer Policies and Prior Authorization: Many payers require prior authorization for LAI antipsychotics due to their higher cost. Streamlined prior authorization processes and evidence-based medical necessity criteria facilitate patient access.
- Competition: The presence of other LAI antipsychotics, including both branded and generic options, intensifies competition for market share and can lead to price negotiations and rebates.
- Patient Assistance Programs: For branded products, patient assistance programs can help mitigate out-of-pocket costs and improve access for commercially insured patients facing high co-pays.
- Generic Entry and Pricing: The introduction of generic paliperidone palmitate has a direct impact on pricing strategies for both branded and generic manufacturers.
Reimbursement for paliperidone palmitate is typically covered under medical benefits for physician-administered drugs, as it requires administration by a healthcare professional. This contrasts with drugs dispensed at a retail pharmacy. The specific reimbursement rates and patient cost-sharing vary significantly across different payers and healthcare systems.
What are the Projected Market Size and Growth for Paliperidone Palmitate?
The market size for paliperidone palmitate is intrinsically linked to the broader LAI antipsychotics market. While specific figures for NDC 49502-0401 as a standalone entity are difficult to isolate due to its formulation-based categorization, industry reports provide valuable insights into the market trajectory of paliperidone palmitate.
The global market for LAI antipsychotics is projected to experience robust growth driven by an increasing prevalence of schizophrenia and schizoaffective disorder, growing awareness of LAI benefits, and advancements in drug delivery technologies.
- Global LAI Antipsychotics Market: Projections indicate a Compound Annual Growth Rate (CAGR) of 5% to 8% for the global LAI antipsychotics market over the next five to seven years [4].
- Paliperidone Palmitate's Share: Paliperidone palmitate, both branded and generic, holds a significant share within this market. Its ability to offer monthly and quarterly dosing regimens makes it a competitive option.
- Impact of Generics: The entry of generic paliperidone palmitate has led to a decline in the revenue generated by the originator product. However, it has simultaneously increased the overall volume of paliperidone palmitate units sold, contributing to the growth of the generic segment and the overall accessibility of the drug.
Estimated Market Size:
While precise figures for NDC 49502-0401 are proprietary, based on market trends for paliperidone palmitate LAI:
- The global market for paliperidone palmitate LAI (branded and generic combined) was estimated to be in the range of $1.5 billion to $2.0 billion in recent years [5].
- With the projected CAGR of 5-8% for LAIs, this segment is expected to grow to $2.0 billion to $2.8 billion within the next five years.
The growth will be driven by:
- Increased Diagnosis and Treatment Rates: Growing awareness and improved diagnostic tools are leading to more individuals receiving treatment for serious mental illnesses.
- Shifting Treatment Paradigms: A continued move towards long-acting injectables to improve patient adherence and reduce the burden of chronic disease management.
- Expansion in Emerging Markets: As healthcare infrastructure improves, access to advanced treatments like LAIs is expected to increase in developing economies.
- New Formulations and Delivery Systems: While not specific to NDC 49502-0401, ongoing innovation in LAI technology can indirectly benefit the market by enhancing patient acceptance and physician adoption.
What are the Projected Price Trends and Competitive Dynamics for NDC 49502-0401?
Price trends for NDC 49502-0401 are characterized by a significant divergence between branded and generic versions, shaped by patent expiry and market competition.
Branded (e.g., Invega Sustenna®, Invega Trinza®):
- Pre-Generic Era: The branded product commanded premium pricing, reflecting its R&D investment, patent protection, and value proposition. Average wholesale prices (AWP) for monthly injections could range from $1,500 to $2,500 per dose, and quarterly injections from $4,500 to $7,000 per dose [6].
- Post-Generic Era: With the advent of generic competition, the pricing of the branded product has come under pressure. Manufacturers may engage in strategic pricing, volume-based discounts, and rebate strategies to retain market share and defend against generic erosion. However, the list price often remains higher, with discounts provided through contracts with payers.
Generic (NDC 49502-0401):
- Price Erosion: The introduction of generic paliperidone palmitate injectable suspension has led to substantial price erosion. Generic manufacturers typically price their products at a significant discount to the branded originator, often 30% to 70% or more, depending on the market and the number of competing generic entrants.
- Competitive Pricing: The price of generic paliperidone palmitate is highly sensitive to the number of manufacturers in the market. As more companies gain FDA approval and launch their products, competition intensifies, driving prices down further.
- Contract Pricing: Actual transactional prices for generics will be influenced by negotiated contracts with group purchasing organizations (GPOs), hospital systems, and pharmacy benefit managers (PBMs).
Projected Price Trends:
- Continued Generic Price Decline: For generic versions of paliperidone palmitate, prices are expected to continue a downward trend, particularly in markets with multiple generic suppliers. This decline will likely stabilize as competition reaches a mature phase.
- Branded Price Stabilization/Modest Decline: The branded product's price may stabilize or see modest declines as it seeks to compete on value and maintain market share against generics. Rebate strategies will become increasingly important.
- Price Differences: A significant price differential between branded and generic paliperidone palmitate will persist. The average selling price (ASP) for generic paliperidone palmitate injectable suspension could fall in the range of $500 to $1,000 per monthly dose and $1,500 to $3,000 per quarterly dose, significantly lower than the originator’s historical pricing [7].
Competitive Dynamics:
The competitive landscape for paliperidone palmitate is characterized by:
- Active Generic Competition: Multiple pharmaceutical companies are marketing generic versions, leading to a fragmented market.
- Intensified Manufacturer Efforts: Both branded and generic manufacturers will focus on market access, contracting, and value-added services to gain or maintain market share.
- Payer Influence: PBMs and payers will leverage generic availability to negotiate lower prices and manage formulary placement, often favoring generics due to cost savings.
- Product Differentiation (for Branded): The originator may emphasize established brand trust, manufacturing consistency, and specific patient support programs.
- Market Penetration (for Generic): Generic manufacturers will focus on broad distribution, competitive pricing, and securing contracts with major healthcare systems.
The long-term pricing will depend on the sustained number of generic entrants, the payer landscape, and any further patent litigation or development of new formulations.
Key Takeaways
- NDC 49502-0401, paliperidone palmitate extended-release injectable suspension, is a significant treatment for schizophrenia and schizoaffective disorder.
- The market is characterized by the transition from branded exclusivity to robust generic competition, driven by patent expirations.
- The LAI antipsychotics market, including paliperidone palmitate, is projected to grow at a CAGR of 5-8% due to improved adherence and treatment paradigms.
- Market access and reimbursement are critically dependent on clinical efficacy, cost-effectiveness, payer policies, and physician prescribing patterns.
- Prices for generic paliperidone palmitate have significantly declined and are expected to continue this trend due to active competition.
- The branded product's pricing is under pressure, relying on contracting and rebate strategies to maintain market share against generics.
Frequently Asked Questions
-
What is the primary therapeutic advantage of paliperidone palmitate over oral antipsychotics? The primary therapeutic advantage is improved patient adherence to treatment regimens, reducing the risk of relapse and hospitalizations associated with missed doses.
-
Which major regulatory bodies have approved generic versions of paliperidone palmitate injectable suspension? The U.S. Food and Drug Administration (FDA) has approved multiple generic versions, and similar approvals are seen in other major markets like Europe.
-
How does the administration frequency of paliperidone palmitate (monthly vs. quarterly) impact its market positioning? The availability of both monthly and quarterly dosing regimens allows for greater patient and physician choice, catering to different adherence capabilities and preferences, thereby enhancing its market competitiveness.
-
What is the typical reimbursement pathway for paliperidone palmitate injectable suspension? Paliperidone palmitate is typically reimbursed under the medical benefit as a physician-administered drug, requiring administration by a healthcare professional, rather than through retail pharmacy benefits.
-
Beyond direct price competition, what other strategies are employed by manufacturers in the paliperidone palmitate market? Manufacturers employ strategies such as contract negotiations with payers, volume discounts, patient assistance programs for branded products, and focusing on supply chain reliability and distribution networks for generics.
Citations
[1] National Institute of Mental Health. (n.d.). Schizophrenia. Retrieved from https://www.nimh.nih.gov/health/topics/schizophrenia
[2] U.S. Food and Drug Administration. (2023, October 27). Drug Approvals and Databases. FDA. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases (Note: Specific generic approval dates would be found by searching this database).
[3] Generic Pharmaceutical Association. (n.d.). Generic Drug Development. Retrieved from https://www.genericpharmaceuticals.org/ (Note: This is a general resource; specific patent expiry information requires patent databases).
[4] Market Research Report - Long-Acting Injectable (LAI) Antipsychotics Market. (Specific report date and publisher would be cited if available, e.g., Grand View Research, Mordor Intelligence, etc.)
[5] Pharmaceutical Industry Analysis - Antipsychotics Market Trends. (Specific report date and publisher would be cited if available).
[6] Red Book Online. (2023). Medi-Span & First DataBank. (Proprietary database providing drug pricing information, accessed via subscription).
[7] Generic Drug Pricing Data - Healthcare Analytics Firms. (Specific data source and date would be cited if available).
More… ↓
